Our finding of an association between copeptin and CVD mortality and stroke events in individuals with diabetes, but not in those without diabetes, is of potential relevance to the recent findings of the EMPA-REG OUTCOME trial, particularly given prior associations of elevated copeptin with renal and cardiac pathology, heart failure and CVD mortality. This evidence concerns the gene AVP and stroke disorder.